Zim Laboratories Share Price Today | Stock Price & Zim Laboratories Share Screener
As of October 5, 2026, the live Zim Laboratories share price (NSE: ZIMLAB) is ₹137.10 on NSE and ₹136.25 on BSE, up 0.06% from the previous close, with shares trading between ₹131.00 and ₹139.49 in today's trading session, and a 52-week range of ₹60.26–₹139.22. Check ZIMLAB annual price range for the annual price range and momentum. Use the Zim Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Zim Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹111 and net income of ₹4, with EBITDA of ₹13, an operating margin of 7.0% and a profit margin of 3.6%.
Zim Laboratories Share Price Chart
Track the current stock price of Zim Laboratories with an interactive chart. Analyse ZIMLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Zim Laboratories stock quote in one place.
The quote of ₹137.10 sits between the 52-week low of ₹60.26 and the 52-week high of ₹139.22, and the latest session moved 0.06% from the previous close.
Zim Laboratories Company Profile - Fundamental Screener
Screen Zim Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ZIMLAB shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE518E01015.
Company Details
Classification
Identifiers and Leadership
Zim Laboratories Balance Sheet Screener
Screen ZIMLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹539, up from ₹472 in 2025.
Latest statistics put total assets at ₹539 and shareholder funds at ₹296, with a leverage ratio of 0.45.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 539 | 472 | 447 | 342 | 342 | 325 | 325 | 329 | 298 | 259 |
| Current Assets | 276 | 231 | 228 | 191 | 212 | 192 | 182 | 194 | 173 | 154 |
| Fixed Assets | 162 | 164 | 161 | 109 | 106 | 107 | 116 | 106 | 94 | 89 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 53 | 54 | 49 | 30 | 20 | 22 | 28 | 22 | 20 | 28 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 296 | 252 | 239 | 200 | 176 | 161 | 154 | 151 | 137 | 118 |
| Share Capital | 54 | 49 | 49 | 49 | 16 | 16 | 16 | 16 | 8 | 8 |
| Reserves & Surplus | 240 | 202 | 190 | 152 | 160 | 145 | 138 | 135 | 129 | 110 |
Zim Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Zim Laboratories income statement and profit fundamentals. Analyze ZIMLAB quarterly results. Zim Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹111 and net profit was ₹4, equal to earnings per unit of ₹0.76, at an operating margin of 7%.
In that period expenses were ₹98, interest cost ₹3 and tax ₹1. The next period listed, 2026-Jun, shows revenue of ₹95 and net profit of ₹-4.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 111 | 95 | 110 | 73 | 91 | 110 | 119 | 83 | 94 | 98 | 106 | 69 | 87 | 97 | 107 |
| Expenses | 98 | 92 | 94 | 68 | 83 | 96 | 102 | 74 | 83 | 85 | 90 | 63 | 77 | 85 | 90 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 13 | 3 | 16 | 6 | 8 | 15 | 17 | 9 | 11 | 13 | 16 | 6 | 11 | 13 | 16 |
| Operating Profit % | 7.00% | 3.00% | 13.00% | 6.00% | 6.00% | 12.00% | 13.00% | 10.00% | 10.00% | 12.00% | 15.00% | 7.00% | 11.00% | 12.00% | 14.00% |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
| Interest | 3 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 1 | 2 | 1 | 2 | 1 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 5 | -6 | 8 | -2 | 0 | 6 | 11 | 1 | 3 | 6 | 10 | 0 | 5 | 7 | 11 |
| Tax | 1 | -2 | 3 | -1 | 0 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 4 |
| Net Profit | 4 | -4 | 5 | -2 | 0 | 4 | 8 | 1 | 2 | 4 | 7 | 0 | 4 | 5 | 7 |
| EPS | 0.76 | -0.75 | 1.01 | -0.38 | -0.09 | 0.90 | 1.66 | 0.18 | 0.49 | 0.82 | 1.48 | 0.05 | 0.85 | 0.98 | 4.33 |
Zim Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen ZIMLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹50, and net cash flow was an inflow of ₹23.
Over the same period, investing activities used ₹55 and financing activities provided ₹28.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 50 | 41 | 16 | 38 | 49 | 32 | 22 | 35 | 37 | 32 |
| Investing Activities | -55 | -40 | -73 | -35 | -14 | -6 | -19 | -21 | -26 | -7 |
Financing and Net Cash | ||||||||||
| Financing Activities | 28 | -9 | 60 | 1 | -33 | -26 | -2 | -15 | -10 | -25 |
| Net Cash Flow | 23 | -8 | 3 | 3 | 2 | 0 | 1 | -1 | 1 | 0 |
Zim Laboratories Shareholding Pattern Screener
See Zim Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Zim Laboratories promoter holding and ownership changes for ZIMLAB on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 30.34%, foreign institutions 0.00%, domestic institutions 0.07% and the public 32.77%, spread across 16,762 shareholders.
The shareholder count was 16,762 in 2026-Mar, compared with 14,510 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 30.34% | 30.36% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.03% | 0.01% | 0.03% | 0.00% | 0.02% | 0.01% | 0.00% |
| DII Holding | 0.07% | 1.33% | 0.24% | 0.24% | 0.24% | 0.20% | 0.00% | 0.11% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.77% | 31.82% | 47.78% | 47.50% | 48.20% | 36.63% | 49.01% | 49.21% |
| Other Holding | 36.81% | 36.46% | 18.71% | 18.96% | 18.30% | 29.89% | 17.72% | 17.42% |
| Shareholder Count | 16,762 | 14,510 | 17,448 | 16,641 | 17,282 | 17,251 | 17,100 | 17,483 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Zim Laboratories. Zim Laboratories dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.50 | 2.68% |
| 2018-March | ₹1.00 | 2.40% |
| 2017-March | ₹0.00 | 0.00% |
Zim Laboratories Stock Index Membership - Nifty & Sensex
See which indices include Zim Laboratories stock. Check ZIMLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Zim Laboratories Market Events Screener - Corporate Actions
Get Zim Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Zim Laboratories stock events that may affect ZIMLAB share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 6, 2026, with a record date of August 6, 2026.
It is followed by Annual General Meeting dated June 29, 2026 and Quarterly Result Announcement dated May 19, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-06 | 2026-08-06 | Quarterly Result Announcement | NA | 2.65% |
| 2026-06-29 | 2026-06-29 | Annual General Meeting | NA | 14.80% |
| 2026-05-19 | 2026-05-19 | Quarterly Result Announcement | NA | -12.16% |
| 2026-02-16 | 2026-02-16 | Extraordinary General Meeting | NA | -5.66% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 7.74% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | 5.86% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -29.01% |
| 2025-06-27 | 2025-06-27 | Annual General Meeting | NA | 27.77% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 5.18% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 5.61% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | 5.94% |
| 2024-06-27 | 2024-06-27 | Annual General Meeting | NA | 2.64% |
| 2022-12-22 | 2022-12-22 | Bonus | 2:1 | 5.37% |
| 2022-06-29 | 2022-06-29 | Extraordinary General Meeting | NA | -18.24% |
| 2018-10-04 | Bonus | 1:1 | - |
Zim Laboratories Competitors Screener - Peer Stocks Comparison
Screen ZIMLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 447,476 | 36.44 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 250,363 | 86.51 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 186,152 | 85.91 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 120,798 | 26.32 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 111,426 | 33.44 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,838 | 99.70 | 6,868 | 22.01% | 890 | 58.00 |
| Mankind Pharma | 105,107 | 48.73 | 14,636 | 14.85% | 1,938 | 64.24 |
| Dr Reddys Laboratories | 104,492 | 32.05 | 35,059 | 3.90% | 4,158 | 69.59 |
| Aurobindo Pharma | 97,682 | 26.36 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,829 | 16.99 | 29,039 | 26.75% | 5,356 | 34.02 |
Zim Laboratories Company Announcements - News & Reports Screener
Screen ZIMLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 5, 2026.
The next most recent announcements are dated September 18, 2026 and September 15, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-05 | Closure of Trading Window | - |
| 2026-09-18 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-09-15 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-08-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-08-12 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-08-12 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-08-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-06 | Earnings Presentation - Q1 FY27 | - |
| 2026-08-06 | Results-Financial Results For 30.06.2026. | - |
| 2026-08-06 | Board Meeting Outcome for Outcome Of The Board Meeting. | - |
| 2026-08-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-31 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30Th June 2026. | - |
| 2026-07-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-13 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-07-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-10 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-06-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-06-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹137.10, within a 52-week range of ₹60.26 to ₹139.22. The P/E ratio is 197.90 and the P/B ratio is 2.49, with earnings per unit of ₹1.19. Market capitalisation stands at ₹722.32 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.